DexCom (NASDAQ:DXCM) Given Overweight Rating at Piper Jaffray Companies

Piper Jaffray Companies restated their overweight rating on shares of DexCom (NASDAQ:DXCM) in a research report released on Monday morning, The Fly reports. Piper Jaffray Companies also issued estimates for DexCom’s Q4 2019 earnings at $0.55 EPS, FY2019 earnings at $1.25 EPS, Q1 2020 earnings at $0.11 EPS, Q2 2020 earnings at $0.24 EPS, Q3 2020 earnings at $0.71 EPS, Q4 2020 earnings at $0.71 EPS, FY2020 earnings at $1.78 EPS, Q1 2021 earnings at $0.23 EPS, Q2 2021 earnings at $0.40 EPS, Q3 2021 earnings at $0.97 EPS and FY2021 earnings at $2.60 EPS.

Several other analysts have also commented on the stock. Oppenheimer raised their price target on shares of DexCom from $180.00 to $205.00 in a research report on Thursday, November 7th. ValuEngine lowered shares of DexCom from a buy rating to a hold rating in a research report on Wednesday, October 2nd. Raymond James raised their price target on shares of DexCom from $172.00 to $189.00 and gave the company an outperform rating in a research report on Thursday, November 7th. BMO Capital Markets raised their price target on shares of DexCom from $180.00 to $190.00 and gave the company an outperform rating in a research report on Tuesday, September 3rd. Finally, Robert W. Baird raised their price target on shares of DexCom from $195.00 to $240.00 and gave the company an outperform rating in a research report on Thursday, November 7th. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $190.67.

NASDAQ:DXCM opened at $218.81 on Monday. The firm has a market capitalization of $19.91 billion, a P/E ratio of 178.34 and a beta of 0.64. DexCom has a 1-year low of $105.05 and a 1-year high of $223.25. The company’s fifty day moving average price is $169.21 and its 200-day moving average price is $151.59. The company has a debt-to-equity ratio of 1.41, a current ratio of 5.63 and a quick ratio of 5.26.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Wednesday, November 6th. The medical device company reported $0.65 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.45. The firm had revenue of $396.30 million for the quarter, compared to analyst estimates of $348.99 million. DexCom had a negative net margin of 12.68% and a positive return on equity of 16.16%. The business’s quarterly revenue was up 48.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.17 earnings per share. Equities analysts anticipate that DexCom will post 1.41 EPS for the current fiscal year.

In other news, insider Andrew K. Balo sold 9,107 shares of DexCom stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $151.56, for a total value of $1,380,256.92. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 10,000 shares of DexCom stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $170.13, for a total transaction of $1,701,300.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 85,963 shares of company stock worth $13,227,047. Company insiders own 1.80% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in DXCM. Price T Rowe Associates Inc. MD lifted its stake in shares of DexCom by 359.4% in the second quarter. Price T Rowe Associates Inc. MD now owns 5,456,834 shares of the medical device company’s stock worth $817,652,000 after buying an additional 4,268,926 shares in the last quarter. Jennison Associates LLC lifted its stake in shares of DexCom by 211.2% in the second quarter. Jennison Associates LLC now owns 1,391,980 shares of the medical device company’s stock worth $208,574,000 after buying an additional 944,642 shares in the last quarter. Nuveen Asset Management LLC lifted its stake in shares of DexCom by 1,781.3% in the second quarter. Nuveen Asset Management LLC now owns 1,107,735 shares of the medical device company’s stock worth $165,983,000 after buying an additional 1,048,855 shares in the last quarter. Waddell & Reed Financial Inc. lifted its stake in shares of DexCom by 1.8% in the second quarter. Waddell & Reed Financial Inc. now owns 1,056,250 shares of the medical device company’s stock worth $158,269,000 after buying an additional 18,247 shares in the last quarter. Finally, Northern Trust Corp lifted its stake in shares of DexCom by 3.0% in the second quarter. Northern Trust Corp now owns 556,521 shares of the medical device company’s stock worth $83,388,000 after buying an additional 16,056 shares in the last quarter. Institutional investors and hedge funds own 98.21% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Story: What is a Real Estate Investment Trust (REIT)?

The Fly

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit